Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 20, Issue 9, 2000, Pages 2156-2161

  Juhan Vague, I ^a   Renucci, J F ^a   Grimaux, M ^b   Morange, P E ^a   Gouvernet, J ^a   Gourmelin, Y ^c   Alessi, M C ^a  

^a TIMONE HOSPITAL   (France)

^b Serbio Genevilliers   (France)

^c Stago Asnières   (France)

Author keywords

Cardiovascular risk; Fibrinogen; Plasminogen activator inhibitor 1; Thrombin activatable fibrinolysis inhibitor

Indexed keywords

ANTIGEN; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ADULT; AGE; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; ENVIRONMENTAL FACTOR; FEMALE; HEMOSTASIS; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RISK FACTOR;

EID: 0033813044     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.20.9.2156     Document Type: Article

References (23)

1. Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N
2. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma
3. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor
4. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties
5. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex
6. Activation of thrombin-activable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C
7. Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor
8. Plasma carboxypeptidases as regulators of the plasminogen system
9. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent
10. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B
11. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor
12. Inducible carboxypeptidase activity: A role in clot lysis in vivo
13. A novel approach to arterial thrombolysis
14. Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature
15. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris: ECAT Study Group: European Concerted Action on Thrombosis and Disabilities
16. Determinants of plasma fibrinogen: Relation to body weight, waist-to-hip ratio, smoking, alcohol, age, and sex: Results from the second MONICA Augsburg survey 1989-1990
17. Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: A family study with part of the Stanislas Cohort
18. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation
19. Assay of procarboxypeptidase U, a novel determinant of the fibrinolytic cascade, in human plasma
20. Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction: The PRIME Study: Prospective Epidemiological Study of Myocardial Infarction
21. PAI-1, obesity, insulin resistance and risk of cardiovascular events
22. Fibrinogen, obesity and insulin resistance
23. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women: A randomized controlled trial